Application of stachyose in preparation of drug for treating castration-resistant prostate cancer
Disclosed is an application of Stachyose in preparation of a drug for treating castration-resistant prostate cancer, belonging to the technical field of biological medicine. The disclosure proposes a new strategy of using Stachyose in combination with an androgen receptor antagonist to prepare a drug for treating CRPC for the first time, and conducts multi-angle and multi-level verification research. The drug composition of the Stachyose in combination with the androgen receptor in the disclosure can be used for treating castration-resistant prostate cancer, and significantly improves the effect of Enzalutamide on inhibiting castration-resistant prostate cancer. The natural compound is applied to the advanced stage of cancer, and has important clinical therapeutic significance.
1 . A method of preparing a composition for treating EPI-001 (EPI)-tolerant or enzalutamide (Enza)-tolerant castration-resistant prostate cancer (CRPC), comprising:
providing Stachyose,
providing an androgen receptor antagonist drug, and
preparing the composition which consists of an effective amount of only the Stachyose and the androgen receptor antagonist drug as active agents, combined with a pharmaceutical excipient,
wherein the androgen receptor antagonist drug is selected from the group consisting of: Enza, EPI, and a combination thereof,
thereby preparing the composition for treating castration-resistant prostate cancer.
2 . A method for treating EPI-001 (EPI)-tolerant or enzalutamide (Enza)tolerant castration-resistant prostate cancer (CRPC), comprising:
administering an effective amount of a composition consisting of only Stachyose and an androgen receptor antagonist drug as active agents, combined with a pharmaceutical excipient, to an EPI/Enza-tolerant CRPC patient in need thereof,
wherein the androgen receptor antagonist drug is selected from the group consisting of: Enza, EPI, and a combination thereof.
3 . The method according to claim 1 , wherein a mass ratio of the androgen receptor antagonist drug to the Stachyose in the composition is (1-8):1.
4 . The method according to claim 1 , wherein the pharmaceutical excipient is one or more of: a solvent, a propellant, a solubilizer, a cosolvent, an emulsifier, a colorant, an adhesive, a disintegrant, a filler, a lubricant, a wetter, an osmotic pressure regulator, a stabilizer, a glidant, a flavoring agent, a preservative, a suspending aid, a coating material, an aromatic agent, an anti-binding agent, an integration agent, a penetration enhancer, a pH regulator, a buffer, a plasticizer, a surfactant, a foamer, a defoamer, a thickener, an inclusion agent, a humectant, an absorbent, a diluent, a flocculant, a deflocculant, a filter aid, and a release retardant.
5 . The method of preparation according to claim 1 , wherein the method further comprises adding one or more carriers to the composition.
6 . The method according to claim 5 , wherein the one or more carriers are selected from: microcapsules, microspheres, nanoparticles, and liposomes.
7 . The method according to claim 1 , wherein the composition is in a dosage form of injections, lyophilized powder for injection, controlled-release injections, liposome injections, suspensions, implants, emboli, capsules, tablets, pills, or oral liquids.